Prescription drugs boost drives J&J forecasts higher, shares rise
Johnson & Johnson boosted its profit forecast for the year on Tuesday after posting better-than-expected quarterly earnings on stronger prescription sales of its psoriasis treatment Stelara and cancer drug Imbruvica.